Glenmark Pharma launches drug for diabetic patients with comorbidities

Glenmark Pharmaceuticals said it has launched a fixed-dose combination for the treatment of diabetes for patients with comorbidities

Glenmark Pharmaceuticals

Press Trust of India New Delhi
Glenmark Pharmaceuticals on Thursday said it has launched a fixed-dose combination for the treatment of diabetes for patients with comorbidities.
The Mumbai-based drug maker said it has become the first company to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed-dose combination for the treatment of adult patients with type 2 diabetes.
Marketed under the brand name Zita D, it contains Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg), and must be taken once daily under prescription to improve glycemic control and prevent complications in adult patients with type 2 diabetes, especially the ones with comorbidities, Glenmark Pharma said in a statement.
"Diabetes is growing in India at an alarming rate, and eight out of every ten diabetic patients suffer from comorbidities," Glenmark Pharmaceuticals EVP & Business Head India Formulations Alok Malik said.
The new drug is well researched and affordable fixed-dose combination, which will significantly improve glycemic control in adult patients, he added.
Glenmark said Zita D is priced at around Rs 14 per tablet for FDC of Teneligliptin 20mg + Dapagliflozin 5mg, and Rs 15 per tablet for FDC of Teneligliptin 20 mg + Dapagliflozin 10 mg per day.
According to IQVIA sales data, for the 12-month period ending September 2022, the market for oral anti-diabetic drugs in India is estimated to be Rs 11,796 crore with an annual growth of 7 per cent against the corresponding period last year.
As per the International Diabetes Federation (IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045.
Out of these, 77 per cent of patients have uncontrolled diabetes.
Moreover, about eight out of ten patients with diabetes also have one or more comorbidity in India, the drug firm stated.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 20 2022 | 12:58 PM IST

Explore News